IOVANCE BIOTHERAPEUTICS, INC. Adjustments to Additional Paid in Capital, Other
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Adjustments to Additional Paid in Capital, Other of $49.45 million for the 12-month period ending 2016-12-31, per its 10-K filed 2019-02-28.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2019-02-28
- IOVANCE BIOTHERAPEUTICS, INC. adjustments to additional paid in capital, other for the quarter ending 2016-12-31 was $98.91M.
- IOVANCE BIOTHERAPEUTICS, INC. adjustments to additional paid in capital, other for fiscal 2016 was $49.45M.
- IOVANCE BIOTHERAPEUTICS, INC. adjustments to additional paid in capital, other for fiscal 2013 was $0.00.
| Period end | Adjustments to Additional Paid in Capital, Other 3 month | Adjustments to Additional Paid in Capital, Other 9 month | Adjustments to Additional Paid in Capital, Other 12 month | Adjustments to Additional Paid in Capital, Other 12 month as first filed |
|---|---|---|---|---|
| 2016-12-31 | $98.91M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $49.45M 10-K · filed 2019-02-28 | -$49.45M 10-K · filed 2017-03-09 | |
| 2016-09-30 | -$49.45M 10-Q · filed 2016-11-04 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |